Medical Treatment of Advanced Renal Cell Carcinoma: Present Options and Future Directions

European Urology, Supplements

Volumn 5, Issue 8, 2006, Pages 619-626

  Boccardo, Francesco M ^a   Guglielmini, Pamela ^a   Tacchini, Laura ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Chemotherapy; Immunotherapy; Metastatic renal cell carcinoma; Targeted therapies

Indexed keywords

AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; ERLOTINIB; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; THALIDOMIDE; VASCULOTROPIN; VATALANIB; VINBLASTINE;

ADOPTIVE IMMUNOTHERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SUSCEPTIBILITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 33646555095     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.03.007     Document Type: Review

References (50)

1. Chow W.H., Devesi S., and Warren J.L. Rising incidence of renal cell cancer in the United States. JAMA 281 (1999) 17-19
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2004. CA. Cancer J Clin 54 (2004) 8-29
3. Linehan W.M., Zibar B., and Bate S.E. Cancer of the kidney and ureter. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer, principles & practice of oncology (2001), Lippincott Williams & Wilkins, Philadelphia 1362-1392
4. Patard J.J., Tazi H., Bensalah K., et al. The changing evolution of renal tumours: a single centre experience over a two-decade period. Eur Urol 45 (2004) 490-493 discussion 493-4
5. Ficarra V., Prayer-Galetti T., Novella G., et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol 43 (2003) 663-669
6. Lam J., Shvarts O., and Pantuck A.J. Changing concepts in the surgical management of renal cell carcinoma. Eur Urol 45 (2004) 692-705
7. Volgezang N.J., Priest E.R., and Borden L. Spontaneous regression of histologically proven pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol 148 (1992) 1247-1248
8. Caraglia M., Vitale G., Marra M., et al. Alpha-interferon and its effects on signal transduction pathways [review]. J Cell Physiol 202 (2005) 323-335
9. McDermott D.F., and Atkins M.B. Application of IL2 and others cytokines in renal cancer cell. Exp Opin Biol Ther 4 (2004) 455-468
10. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon alfa as a comparative treatment for clinical trails of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
11. Coppin C., Porzsolt F., Awa A., et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) CD001425
12. Pyrhonen S., Salminen E., Ruutu M., et al. Prospective randomised trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 353 (1999) 14-17
13. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a or both in metastatic renal cell carcinoma. N Engl J Med 338 (1998) 1272-1278
14. Motzer R.J., Murphy B.A., Bacik J., et al. Phase III trial of interferon alfa-2a with or without 13-cis-transretinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18 (2000) 2972-2980
15. Fossa S.D., De Garis S.T., Heier M.S., et al. Recombinant interferon-α-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 57 (1986) 1700-1704
16. Neidhart J.A., Anderson S.A., Harris J.E., et al. Vinblastine fails to improve response of renal cancer to interferon alpha-1: high response rate in patients with pulmonary metastases. J Clin Oncol 4 (1991) 408-413
17. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 (1985) 1485-1492
18. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant IL2 therapy. J Clin Oncol 13 (1995) 688-696
19. Fisher R.I., Rosenberg S.A., and Fyfe G. Long-term survival update for high dose recombinant IL2 in patients with renal cell carcinoma. Cancer J Sci Am 6 (2000) S55-S57
20. Dutcher J.P., Fisher R.I., Weiss G., et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for renal cell cancer: five year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 3 (1997) 157-162
21. Atzpodien J., Lopez Hanninen E., Kirchner H., et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13 (1995) 497-501
22. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
23. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
24. Atkins M.B., and McDermott D.F. Results of the Cytokine Working Group phase III trial of high dose IL2 vs low dose IL2 and IFN therapy in patients with metastatic renal cell carcinoma. Cancer Invest 21 (2003) S87-S88
25. Negrier S., Perol D., Ravaud A., et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc ASCO (2005) (abstract no. 4511)
26. Patard J.J., Kim H.L., Lam J.S., et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22 (2004) 3316-3322
27. Uemura H., Nakagawa Y., Yoshida K., et al. MN-CA IX/G250 as potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81 (1999) 741-746
28. Ravaud A. Cell therapy in renal cell carcinoma. Bull Cancer 90 (2003) 711-721
29. Child R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343 (2000) 750-758
30. Yagoda A., Abi-Rached B., and Petrylak D.P. Chemotherapy for metastatic renal-cell carcinoma:1983-1993. Semin Oncol 22 (1995) 42-60
31. Ruiz J.A., Raftopoulos H., and Petrylak D.P. Chemotherapy for metastatic renal-cell carcinoma (RCC). In: Bukowski R.M., and Novick A.C. (Eds). Renal cell carcinoma: molecular biology, immunology and clinical management (2000), Humana Press, Totowa, NJ 283-300
32. De Mulder P.H., Weissbach L., Jakse G., et al. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37 (1996) 491-495
33. Oevermann K., Buer J., Hoffmann R., et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83 (2000) 583-587
34. Kirkman H. Estrogen induced tumors of the kidney in the Syrian hamster. NCI Monogr 1 (1959) 1-59
35. Bloom H.G.C. Hormone-induced and spontaneous regression of metastatic renal cancer. Cancer 32 (1973) 1066-1071
36. Bono A.V. Steroid hormones and hormonal treatment in renal cell carcinoma. In: deKernion J., and Pavone-Maculuso M. (Eds). Tumors of the kidney (1986), Williams & Wilkins, Baltimore 205-227
37. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
38. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
39. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
40. Spigel D.R., Hainsworth J.D., and Sosman J.A. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma: update of a phase II multicenter trial. J Clin Oncol (Meeting Abstracts) 23 (2005) 4540
41. George D., Michaelson D., and Oh W.K. Phase I study of PTK787/ZK222584 (PTK/ZK) in metastatica renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 21 (2003) 1548
42. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
43. Ratain M.J., Eisen T., Stadler W.M., et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial of Sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 23 (2005) 4544
44. Escudier B., Szczylik C., and Eisen T. Randomized phase III trial of the Raf kinase and VEGFR inhibitor Sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 23 (2005) 4510
45. Escudier B., Szczylik C., and Eisen T. Randomized phase III trial of the multi-kinase inhibitor Sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 2 (2005) 794
46. Robert C., Lassau N., Angevin E., et al. Phase I trial of sorafenib in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma. Eur J Cancer Suppl 3 (2005) 883
47. Gollob J.A., Moran K., Ritchmond T., et al. Phase two trial of sorafenib in combination with interferon alpha-2b in patients with metastatic renal cell carcinoma. Eur J Cancer Suppl 3 (2005) 795
48. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
49. Motzer R.J., Rini B.I., and Michaelson M.D. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 23 (2005) 4508
50. Beeram M., Rowinsky E.K., Weiss G.R., et al. A phase II, pharmacokinetic (PK) and biological correlative study of O51-774 (Tarceva) in patients with advanced renal cell carcinoma, with FDG-PET imaging: evidence of durable stable disease and antitumor activity. Eur J Cancer Suppl 2 (2004) 111